<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146312</url>
  </required_header>
  <id_info>
    <org_study_id>201773</org_study_id>
    <nct_id>NCT03146312</nct_id>
  </id_info>
  <brief_title>Effect of a Multivitamin/Multimineral/Phytochemical Dietary Supplement on Indices of Human Health</brief_title>
  <official_title>Effect of a Multivitamin/Multimineral/Phytochemical Dietary Supplement on Gene Expression, Epigenetics and Nutritional Status in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>USANA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>USANA Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global transcriptomics and epigenetic pilot study designed to identify changes in&#xD;
      gene expression and DNA methylation patterns following the consumption of an&#xD;
      MVM/phytochemical supplement in a small group of healthy subjects. We hypothesize that&#xD;
      genome-wide transcriptional and epigenetic studies will elucidate the molecular mechanisms&#xD;
      underlying the health benefits associated with MVM/phytochemical supplementation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is considerable controversy regarding the benefit of widespread dietary supplement use,&#xD;
      in particular widespread MVM use. The controversy persists because of a marked incongruity in&#xD;
      nutrition research: on one hand, many studies indicate that MVM supplement consumption yields&#xD;
      few - if any - demonstrable health benefits, yet on the other hand, numerous findings&#xD;
      indicate most Americans do not consume the RDA of a variety of nutrients, particularly&#xD;
      vitamins and minerals, and are becoming increasingly under-nourished. Nutrigenomics offers a&#xD;
      unique opportunity to address this controversy, as it can identify subtle changes in gene&#xD;
      expression and epigenetic signatures immediately following a nutritional intervention -&#xD;
      changes which may be indicative of improved health status and which may otherwise remain&#xD;
      undetectable through other clinical endpoints for a considerable period of time, even into&#xD;
      future generations.&#xD;
&#xD;
      Hypothesis: The investigators hypothesize that MVM/phytochemical supplementation will result&#xD;
      in transcriptional and epigenetic changes consistent with an enhancement in human health&#xD;
      status. Moreover, the investigators hypothesize that MVM/phytochemical supplementation will&#xD;
      alter markers of cardiovascular, antioxidant, nutritional as well as inflammatory status in a&#xD;
      manner indicative of improved health.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      This will be a randomized, double blind, placebo controlled, parallel arm design conducted&#xD;
      over a 4-week period. 50-60 healthy subjects will be recruited and, if eligible for the&#xD;
      study, matched by age, sex and ethnicity and randomized in a 1:1 ratio to either of two&#xD;
      interventions:&#xD;
&#xD;
        1. Daily consumption of the control supplement (placebo)&#xD;
&#xD;
        2. Daily consumption of the MVM/phytochemical supplement (treatment)&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Blood will be collected at baseline and after the 4-week intervention. At each time point,&#xD;
      PBMCs will be collected, and DNA and RNA extracted for genome-wide gene expression and DNA&#xD;
      methylation analyses. Serum and plasma will also be collected in order to assess clinical&#xD;
      markers related to cardiovascular, nutritional, antioxidant and inflammatory status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Actual">June 8, 2017</completion_date>
  <primary_completion_date type="Actual">June 8, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression</measure>
    <time_frame>4 weeks</time_frame>
    <description>Gene expression measured by microarray</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>4 weeks</time_frame>
    <description>change in inflammatory markers between MVM/Phytochemical Supplement and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Health</measure>
    <time_frame>4 weeks</time_frame>
    <description>change in markers of cardiovascular health between MVM/Phytochemical Supplement and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>4 weeks</time_frame>
    <description>change in markers of nutritional status between MVM/Phytochemical Supplement and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress/Antioxidant Status</measure>
    <time_frame>4 weeks</time_frame>
    <description>change in oxidative stress markers between MVM/Phytochemical Supplement and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetics</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes in DNA methylation patterns</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>MVM/phytochemical supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a multi-vitamin, multi-mineral, phytochemical supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MVM/phytochemical supplement</intervention_name>
    <description>Consumption of an MVM/phytochemical supplement for 4 weeks</description>
    <arm_group_label>MVM/phytochemical supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Consumption of a placebo tablet identical in size, shape and color to the treatment tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide a signed Informed Consent prior to entry in the study.&#xD;
&#xD;
          -  Are in generally good health.&#xD;
&#xD;
          -  Comprehensive Metabolic Panel results reported within normal reference ranges&#xD;
&#xD;
          -  Body Mass Index of 18.5 - 30.&#xD;
&#xD;
          -  Systolic blood pressure of 90-130 mm Hg; diastolic blood pressure of 60-90 mm Hg.&#xD;
&#xD;
          -  Fasting blood glucose from 65-110 mg/dl.&#xD;
&#xD;
          -  Total cholesterol level of &lt;240 mg/dl&#xD;
&#xD;
          -  LDL cholesterol of &lt;130 mg/dl&#xD;
&#xD;
          -  Triglyceride level of &lt;150 mg/dl.&#xD;
&#xD;
          -  Have good venous access.&#xD;
&#xD;
          -  Must be able to swallow tablets and pills&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, trying to become pregnant, or breast feeding.&#xD;
&#xD;
          -  Chronic or acute use of prescription or OTC medications that may interfere with&#xD;
             absorption of the test supplement.&#xD;
&#xD;
          -  Consumption of a multivitamin/mineral or other dietary supplement for more than 5 days&#xD;
             within 30 days of the screening visit.&#xD;
&#xD;
          -  Gastrointestinal conditions that may affect consumption of the treatment or placebo&#xD;
             tablets.&#xD;
&#xD;
          -  insulin-dependent and orally controlled diabetics&#xD;
&#xD;
          -  Scheduling difficulties or lack of transportation&#xD;
&#xD;
          -  Have participated as a subject in any other clinical study within 30 days of the&#xD;
             screening visit&#xD;
&#xD;
          -  A history of alcohol or substance abuse within 2 years&#xD;
&#xD;
          -  Significant constipation or diarrhea&#xD;
&#xD;
          -  Allergies or intolerance to turmeric, curcumin or related products&#xD;
&#xD;
          -  Inability or difficulty swallowing tablets and pills&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Levy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USANA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USANA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene expression</keyword>
  <keyword>gene array</keyword>
  <keyword>epigenetics</keyword>
  <keyword>DNA methylation</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

